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Objective Fear of recurrence (FOR) is a key concern among survivors of all cancers. In pros-
tate cancer, FOR varies with health and treatment type, but little is known about how survivors'
appraisals of their treatment, and in particular, their level of regret over treatment decisions may
affect this.
Methods A total of 1229 prostate cancer survivors between 2‐ and 5‐years postdiagnosis
were invited to complete a postal questionnaire including a FOR scale, Decisional Regret Scale,
and the European Organization for Research and Treatment of Cancer QLQ C30 health‐related
quality of life (HRQoL) instrument. Multiple regression analysis explored the impact of 3 blocks
of factors on FOR: (1) demographic characteristics and disease extent, (2) primary treatment
received and health status (treatment side effects and HRQoL), and (3) treatment appraisals, spe-
cifically satisfaction with information received regarding treatment and level of regret experi-
enced over treatment decisions.
Results The final multivariable model explained 27% of variance on FOR. Significant corre-
lates of lower FOR included having localised disease, having undergone an invasive treatment,
as well as health status (higher HRQoL and fewer ongoing side effects). Beyond this, appraisals
of treatment significantly contributed to the model: More decisional regret and lower satisfaction
with information received were associated with higher FOR.
Conclusion These findings suggest that FOR may be mitigated by providing survivors with
more information regarding treatment choices and the treatment itself so that men can make
well‐informed decisions and experience less future regret.
Sensitivity analysis for variables predicting FOR among prostate cancer survivors is not suspected
of having a recurrence.
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making1 | BACKGROUND
In recent years, the incidence of prostate cancer (PC) has been increas-
ing internationally,1 with PC, the most common invasive cancer among
men, accounting for approximately 40% of male cancer survivors in
developed countries.2 While this increased incidence may be due to
the upsurge in prostate specific antigen testing, recent research sug-
gests such testing has no effect on mortality rates.3 However, thewileyonlinelibrary.com/jourrange of treatment options available, including radical prostatectomy
(RP), external beam radiotherapy (ERBT), brachytherapy (BT), and
androgen deprivation therapy (ADT), has contributed to 5‐year survival
rates of nearly 100%.4 Yet, despite this good prognosis, a diagnosis of
PC can be accompanied by numerous adverse psychological effects,
including anxiety and depression.5 These feelings are often exacer-
bated by—or even attributed to—worry over cancer, and in particular,
a fear that the cancer will return or progress.6 Typically referred to asCopyright © 2017 John Wiley & Sons, Ltd.nal/pon 1825
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vors,7,8 second only to concerns over sexual dysfunction.9
Given the detrimental effect that FOR can have on various aspects
of well‐being,10 the importance of recognising and seeking to treat this
is widely acknowledged.11 In PC, the negative impact of this worry is
evident, with higher FOR associated with lower quality of life (QOL),
higher distress, and more physical problems in survivors.8 Conversely,
lower FOR has been shown to significantly correlate with better men-
tal health scores.10 In addition, although FOR often improves after PC
treatment, it does not disappear nor change substantially in the 2 years
thereafter.7 While a handful of studies have begun to explore what
exacerbates FOR in PC,7–9,12 these studies are often limited to
survivors undergoing a particular treatment (eg, RP), have small
samples, or focus on a limited range of sociodemographic and clinical
variables. A more thorough analysis of potential correlates of FOR in
PC is therefore merited.
Understanding the role that cognitive appraisals play in the
process may offer insights into steps that may be taken to mitigate
FOR.12 One of the key influences on FOR may be survivors' experi-
ence and appraisals of their treatment; yet few studies have systemat-
ically investigated this as distinct from the treatment itself. While there
has been a move for patients to have a more active role in their treat-
ment choice, PC patients are often not well informed about treatments
and their consequences.13 PC treatments are often accompanied by
significant and long‐lasting adverse side effects including urinary
incontinence, sexual dysfunction, bowel problems, fatigue, and insom-
nia.14,15 While survivors can adapt to such negative outcomes,16 these
effects can have a detrimental impact on QOL, making it difficult to
cope postdiagnosis.17 Any side effects experienced are likely to
contribute to FOR, but this may be exacerbated further should patients
feel ill‐informed as to what to expect from their treatment. Moreover,
although generally low in PC survivors, a significant minority
experience considerable treatment regret,18–21 which could have the
potential to influence FOR.
The aim of this study is to investigate the associations between PC
survivors' treatment appraisals and FOR. Specifically, we hypothesise
that lower satisfaction with information received regarding treatment
and higher treatment regret will be associated with greater FOR after
controlling for established correlates, including sociodemographic and
clinical factors, treatment received, and health status.2 | METHODS
2.1 | Participants
This study formed part of the PiCTure (prostate cancer treatment, your
experience) study—a project involving PC survivors in the Republic of
Ireland and Northern Ireland.22,23 This aspect of the study was limited
to survivors in Republic of Ireland. Following ethical approval from the
Irish College of General Practitioners, PC survivors at least 2‐year
postdiagnosis were identified from the population‐based National
Cancer Registry, Ireland. Following screening for eligibility by general
practitioners, 4453 survivors were invited to complete a postal
questionnaire between April and September 2012. In addition to acore questionnaire administered to all survivors, those who were less
than 5‐year postdiagnosis (N = 1229) were asked to complete a FOR
scale. We focused on this subset of participants in the current analysis.3 | INSTRUMENTS
3.1 | Fear of recurrence
Fear of recurrence was measured using a 5‐item scale,24,25 previously
validated in PC populations.7,9 This requires survivors to report worries
over cancer (“I will probably relapse within the next 5 years”, “My fear
of cancer getting worse gets in the way of my enjoying life”, “Because
cancer is unpredictable, I feel I cannot plan for my future”, and “I am
afraid of my cancer getting worse”) as well as one item relating to opti-
mism over prognosis (“I am certain that I have been cured of cancer”).
Items are scored on a 5‐point Likert scale with total values
standardised to provide a score of 0 to 100 (higher scores correspond
to greater FOR). Reliability for this measure was good in our sample
with a Cronbach α of .84.3.2 | Sociodemographic and clinical information
Participants provided sociodemographic information including age,
marital status, employment status, and highest level of education.
Respondents were classified by disease extent (localised vs locally
advanced/advanced) at time of diagnosis on the basis of clinical stage
and Gleason Grade (GG) as obtained from National Cancer Research
Institute records. Survivors with stage I/II disease and a GG of 2 to 7
at diagnosis were considered to have localised disease, whereas those
having stage 3 to 4 with any GG were classified as having locally
advanced/advanced disease. Survivors having any other combinations
of stage and GG were excluded.3.3 | Treatment and health status
As described previously,22 survivors were classified according to
primary treatment received, providing a single variable broadly captur-
ing both the main treatment(s) and their invasiveness. Categories were
RP, EBRT with concurrent ADT within 6 months, and EBRT without
concurrent ADT, BT, and ADT alone. Those who had not been treated
but had undergone observation/surveillance only (ie, watchful waiting
and/or active surveillance) were also included.
Survivors indicated if they were currently experiencing any side
effects from their treatment, including urinary incontinence, loss of
sexual desire, bowel problems, breast swelling/tenderness, sweats or
hot flashes, fatigue, and/or depression.26 A total number of ongoing
side effects were computed.
The Global Health Score (GHS) subscale of the European
Organization for Research and Treatment of Cancer27 QLQ30 was
used as a general measure of health‐related quality of life (HRQoL).
This is derived from 2 items measuring general health (“How would
you rate your overall physical condition during the past week?”) and
perceived QOL (“How would you rate your overall quality of life during
the past week?”). Responses are measured on a 7‐point Likert scale
MAGUIRE ET AL. 1827(from poor to excellent) and standardised into a score27 of 0 to 100.
Higher GHS indicates better HRQoL.3.4 | Appraisals of treatment: satisfaction with
treatment information and decisional regret
Survivors were asked to reflect on how satisfied they were with the
amount of information given to them about their treatment overall
using a single item rated on a scale of 1 (not at all satisfied) to 7
(extremely satisfied). The Decisional Regret Scale28 was used toTABLE 1 Descriptive statistics for prostate cancer survivors
Categorical Variables No.
Education
Primary 225
Secondary 342
Third level or higher 223
Missing 27
Total 817
Marital status
Married/cohabiting 658
Other 151
Missing 8
Total 817
Employment status at diagnosis
Employed/self‐employed 369
Other 399
Missing 49
Total 817
Disease classification at diagnosis
Localised 488
Advanced 130
Missing 199
Total 817
Primary treatment
RP 258
ERBT with ADT 156
ERBT without ADT 253
BT 65
ADT only 44
Surveillance 27
Missing 14
Total 817
Continuous variables Mean
Survivor age 68.48
Time since diagnosis (years) 3.41
Global health score (GHS) 71.61
Number of side effects 2.16
Regret over decision 18.02
Satisfaction with info received 6.04
FOR 29.42
Abbreviations: ADT, androgen deprivation therapy; BT, brachytherapy; ER
prostatectomy.measure survivor's regret. Here, participants were asked to reflect on
the entire treatment experience by rating their agreement with 3 posi-
tively phrased (“It was the right decision”, “I would go for the same
choice if I had to do it over again”, and “The decision was a wise one”)
and 2 negatively phrased (“I regret the choice that was made”, and
“The choice did me a lot of harm”) statements on a scale of 1 (strongly
agree) to 5 (strongly disagree). After positively phrased items are
recoded, scores are summed and standardised to give rise to a value
of 0 to 100 (higher scores reflect higher regret). This scale has good psy-
chometric properties28 with a Cronbach α in our sample of .85.% FOR
27.5 31.0
41.9 29.7
27.3 27.6
3.3
100
80.5 28.7
18.5 32.8
1.0
100
45.2 26.8
48.8 31.1
6.0
100
59.7 26.9
15.9 35.9
24.4
100
31.6 25.5
19.1 30.9
31.0 30.1
8.0 27.7
5.4 41.1
3.3 38.0
1.7
100
SD Range Possible range
7.87 47‐91 18+
1.13 2‐5 2‐5
21.15 0‐100 0‐100
1.72 0‐8 0‐8
19.56 0‐100 0‐100
1.34 1‐7 1‐7
20.97 0‐100 0‐100
BT, external beam radiotherapy; FOR, fear of recurrence; RP, radical
1828 MAGUIRE ET AL.3.5 | Possible recurrence
Clinical information on recurrence was not available. However, if
survivors received chemotherapy or received ADT or ERBT more than
6 months after their primary treatment, they were classified as having
evidence of a possible recurrence.223.6 | Statistical analysis
A hierarchical multiple regression model was developed to examine the
impact of 3 blocks of factors on FOR: (1) sociodemographic character-
istics (age, education, employment status, and marital status) and
disease extent at diagnosis, (2) primary treatment type and health
status (number of side effects and HRQoL), and (3) treatment
appraisals (treatment regret, and satisfaction with treatment). Descrip-
tive statistics were calculated including means, ranges, and standard
deviations. No violations regarding assumptions of normality, linearity,
and homoscedasticity were observed. Examination of correlations
amongst independent variables revealed no problems with
multicollinearity. Associations with FOR were assessed using 2‐sided
t tests and P‐values of <.05 considered significant.
A sensitivity analysis was performed where the model was rerun
excluding survivors suspected of having a recurrence (excluded
n = 222; 27%).4 | RESULTS
4.1 | Survivor characteristics
Of the 1229 eligible survivors, 817 (response rate 66.5%) completed
the questionnaire. Table 1 displays frequency information and meanTABLE 2 Hierarchical regression analyses for variables predicting FOR am
Variables
Step 1: sociodemographic characteristics and disease extent
Age −
Education
Marital status (other = 0; married/cohabiting = 1) −
Employment status (other = 0; employed = 1) −
Disease classification (localised = 0; locally advanced/advanced = 1)
R2 Change = 0.05
Step 2: treatment and health‐related factors
Primary treatment (lower = more invasive)
Current side effects of treatment (higher = more side effects)
GHS (higher = better HRQoL) −
R2 Change = 0.18
Step 3: appraisals of treatment
Satisfaction with information received (higher = greater satisfaction) −
Regret over treatment decision (higher = greater regret)
R2 Change = 0.04
R2 = 0.27
Statistical significance:
*p < .05;
**p < .01;
***p < .001FOR scores for the categorical variables and descriptive statistics for
the continuous variables. The majority of survivors (79%) had localised
disease and had undergone some form of invasive treatment, with RP
(32%) and ERBT without concurrent ADT (32%) the most common.
On average survivors reported 2.16 ongoing side effects from
their treatment (SD = 1.72) with a mean HRQoL of 71.61 (SD = 21.15),
most were satisfied with the information they received regarding
treatment (M = 6.04; SD = 1.34). The mean Decisional Regret score
of 18.02 suggests that levels of regret amongst were reasonably low,
yet there was considerable variation here (SD = 19.52). For instance,
28.3% experienced no regret whatsoever (classified as a score of 0),
while 14.5% of survivors experienced high levels of regret (a score
above 50).
Fear of recurrence was low on average (M = 29.42; SD = 20.97),
yet the majority of survivors (61%) reported a score of above 25, and
18.6% experienced scores over 50.
4.2 | Multiple regression analysis
Table 2 displays the results of the regression analysis. Block 1
(sociodemographic characteristics and disease extent) explained 4.5%
of variance in FOR, which was statistically significant (p < .001). Treat-
ment and health‐related factors (Block 2) explained an additional
18.0% of the variance (p < .001), while treatment appraisals (Block 3)
contributed a further 4.3% of variance (p < .001). The model as a whole
was significant (p < .001) and explained 26.8% of variance in FOR.
Consistent with our hypotheses, both treatment regret (β = .17,
p < .001) and satisfaction with information received regarding treat-
ment (β = −.08, p = .003) were significantly associated with FOR after
adjusting for sociodemographic, disease, treatment, and health‐related
factors. Specifically, the lower the survivor's satisfaction surroundingongst prostate cancer survivors
β p t B SE CI 95%
.02 .57 −0.57 −0.06 0.11 −0.27 0.15
.01 .87 0.16 0.15 0.94 −1.69 1.99
.05 .17 −1.38 −2.72 1.97 −6.58 1.14
.05 .19 −1.31 −2.13 1.62 −5.32 1.06
.12** .00 3.40 6.07 1.79 2.56 9.58
.15*** .00 4.00 2.19 0.55 1.11 3.26
.14*** .00 3.78 1.64 0.43 0.79 2.49
.29*** .00 −7.72 −0.27 0.03 −0.34 −0.20
.08* .03 −2.20 −1.22 0.55 −2.31 −0.13
.17*** .00 4.64 0.18 0.04 0.10 0.25
MAGUIRE ET AL. 1829information received and the higher the regret over treatment decision
making, the higher the FOR.
A further 4 variables were associated with higher FOR: lower
HRQoL (β = −.29, p < .001); less invasive treatments (β = .15,
p < .001); advanced disease (β = .12, p < .001); and more current side
effects (β = .14, p < .001).4.3 | Sensitivity analysis
Fear of recurrence did not differ significantly between survivors
suspected of having a recurrence and those who were not (p > .05).
When the analysis was rerun excluding those suspected of a
recurrence, the same 6 variables were significantly correlated with
FOR, with similar coefficients as in the original model (see supplemen-
tary table). The only difference here was that employment status
emerged as an additional correlate of FOR, such that those who were
employed at diagnosis had lower FOR (β = −.09, P = .04).5 | CONCLUSIONS
The finding that the majority of PC survivors in our study experienced
at least some worry over cancer recurrence, even those who had no
suspected evidence of such a recurrence, is in keeping with previous
research.7,11 Our research goes beyond previous work in that we have
shown that men's appraisals of their treatment are significantly associ-
ated with FOR, even after adjusting for factors with previously
established relationships.5.1 | Treatment appraisals and FOR
Both treatment regret and satisfaction with information received
regarding treatment reflect aspects of a survivor's subjective appraisal
of their treatment experience. Our findings show how such elements
relate to FOR in addition to more objective factors such as cancer
stage and health status. This is broadly consistent with the common
sense model of FOR,29 which holds that FOR is influenced by one's
illness representations. It is reasonable to assume that how a survivor
views their illness and its treatment forms part of this representation
and therefore may impact on FOR. For example, while decisional regret
was reasonably low amongst our sample on average, a finding consis-
tent with previous research,18–21 its association with FOR illustrates
the negative implications, such regret may have on survivor well‐being.
Indeed, regret over treatment was second only to HRQoL as an FOR
correlate, highlighting the significance that treatment decisions may
have on later fears and worries.
While little work has focused on the association between
decisional regret and FOR, the importance of minimising such regret
in health care decisions has been recognised.30,31 In PC, research has
shown how regret can vary with treatment type, with survivors opting
for RP or BT more likely to regret their treatment decisions.19,20 Other
strong predictors of regret include general health and side effects
experienced.18,20 In our study, however, regret was significantly
associated with FOR even after controlling for these factors, implying
that health status and treatment are not sufficient in explaining the
relationship between the 2. This shows that any PC survivor whoexperiences treatment regret may be at risk of higher levels of FOR,
regardless of the treatment(s) they have undertaken or their health
status/HRQoL.
We also found that survivors' level of satisfaction with the
information received regarding treatment was associated with FOR,
pointing to a clear need for health care professionals to provide survi-
vors with sufficient information regarding their treatment options.13
The relationship between overall treatment satisfaction and FOR has
previously been documented in patients who had undergone RP.32
However, this concept of treatment satisfaction could incorporate
many factors including survivors' views of the side effects experienced,
the time and cost involved in the treatment, as well as their interac-
tions with health care professionals. Our study has isolated a number
of key factors that relate to survivors' appraisal of their treatment,
which offer some insight into how potentially modifiable factors can
influence FOR. Specifically, our results imply that to reduce fears of
recurrence, survivors must be happy with the amount of information
received regarding treatment and feel comfortable with their
decisions.
These findings strengthen the need for health care professionals
to support survivors in making fully informed treatment decisions to
ensure they are satisfied with information and to guard against future
feelings of regret. Given the self‐accountable nature of regret,33 it is
also important that, when making decisions regarding treatment,
survivors feel in control. This relates to the notion of health‐related
self‐efficacy, which has been shown to mediate the relationship
between symptoms and FOR in PC survivors.12 Health‐related self‐
efficacy may be facilitated by decision‐making aids.12 Such interven-
tions may lead to more positive appraisals regarding treatment thereby
reducing uncertainties regarding prognosis and mitigating FOR.5.2 | Other factors associated with FOR
As expected, FOR was higher in those diagnosed with more advanced
disease, which may reflect a genuinely greater risk of recurrence. This
is consistent with previous work, which has shown that both stage and
GG have associations with FOR.11,34 Interestingly, no socio-
demographic factors were associated with FOR. The finding that
younger age had no relationship with cancer‐related worry contradicts
some previous studies.8,34 However, a comprehensive review of the
FOR literature34 suggests that a number of inconsistencies exist
regarding the role of demographics in FOR. This suggests that there
is no “typical” individual (in sociodemographic characteristics at least)
who is more likely to suffer from FOR, implying all patients are poten-
tially at risk at diagnosis.
Our findings do provide evidence for the role of treatment in FOR.
Specifically, those survivors who had received more invasive forms of
treatment such as RP had lower FOR than those who had less invasive
treatment such as ADT. Previous longitudinal analysis showed that
survivors undergoing RP had a reduction in FOR after surgery,7 which
is broadly consistent with our findings; however, no research has
compared a range of PC treatments. Our results suggest that those
survivors undergoing RP or ERBT may feel that their cancer has been
more effectively treated and therefore less likely to recur. Indeed,
the perception that more invasive treatments such as surgery can
1830 MAGUIRE ET AL.reduce the risk of cancer has been documented in other populations.35
Conversely, our results suggest that a less interventionist approach to
treatment (watchful waiting/active surveillance) may be associated
with higher FOR. A possible explanation for this may lie with the
uncertainty that abounds for patients undergoing surveillance.36
Perhaps, the regular prostate specific antigen testing (and sometimes
prostate biopsies) and the knowledge that they are being monitored
lead survivors to believe that there is a genuine risk of progression.
Given that this is a commonly adopted treatment for PC survivors,
especially those deemed low risk,37 it is important that health care
professionals act to alleviate any concerns such patients may have.
Given the well‐established associations between physical health
and FOR,38 it is not surprising that fears were higher in survivors
who reported lower HRQoL. Indeed, the factor most strongly related
to FOR was GHS—a finding reflective of extant literature in PC.6
Furthermore, we found that FOR was higher in survivors who reported
a greater number of ongoing side effects.34 This might be because side
effects act as an ongoing reminder to survivors of their cancer diagno-
sis, triggering concerns regarding recurrence. These findings, in
conjunction with the fact that side effects are common within PC
survivors, even long after treatment has occurred,26 further highlight
the need to ensure greater use of the range of medications and other
supports available to treat side effects.
Consistent with our finding that treatment appraisals impact on
FOR, these results demonstrate how survivors' subjective appraisals
of their well‐being are also important influences. This is again in keep-
ing with the common sense model model of FOR,29 which holds that
illness representations can include survivors' own appraisals of their
physical symptoms, even those unrelated to their cancer diagnosis
see also Easterling and Leventhal.395.3 | Study limitations
While this study entailed a comprehensive analysis of possible factors
associated with FOR, it does have a number of limitations. We only
focused on survivors less than 5‐year postdiagnosis, so we cannot
say anything about how treatment appraisals might affect FOR in the
longer term. The cross‐sectional design means we cannot be entirely
certain of the direction of the relationship between FOR and treatment
appraisals. The presence of a third variable associated with both
factors cannot be ruled out—for example, it is possible that depression
(eg, that induced by ADT) could cause both high FOR and treatment
regret. There are also limitations with some of the measures used.
Our measure of satisfaction with treatment information received was
only assessed via a single item, while our measure of HRQoL only
examined survivors' appraisals of health over the last week rather than
since treatment occurred. It is also possible that our measure of
recurrence used for the sensitivity analysis did not provide a definite
indication of whether recurrence had occurred, given that we did not
have access to medical records. Another issue, not unique to this
study, is how best to conceptualise FOR given the debate surrounding
how to measure this.40 Nevertheless, our study controlled for various
factors previously shown to be associated with FOR in PC, and despite
some missing data, included a sample of PC survivors derived from a
population‐based sampling frame.5.4 | Clinical implications
The fact that FOR is a reasonably common experience, in spite of
generally good prognosis in PC, suggests that those involved in the
follow‐up of PC survivors must be sensitive to such concerns.
Survivors' treatment appraisals, specifically reflections of the treat-
ment experience, are associated with worries over recurrence. These
findings suggest that FOR may be mitigated by making survivors fully
aware of the options available regarding treatment (and their possible
consequences), supporting well‐informed treatment decision making,
and assisting survivors in their appraisal of treatment and management
of any resultant side effects.
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